Abstract Personal genome sequencing is increasingly utilized by healthy individuals for predispositional screening and other applications. However, little is known about the impact of 'genomic counseling' on informed decision-making in this context. Our primary aim was to compare measures of participants' informed decision-making before and after genomic counseling in the HealthSeq project, a longitudinal cohort study of individuals receiving personal results from whole genome sequencing (WGS). Our secondary aims were to assess the impact of the counseling on WGS knowledge and concerns, and to explore participants' satisfaction with the counseling. Questionnaires were administered to participants (n = 35) before and after their pre-test genomic counseling appointment. Informed decisionmaking was measured using the Decisional Conflict Scale (DCS) and the Satisfaction with Decision Scale (SDS). DCS scores decreased after genomic counseling (mean: 11.34 before vs. 5.94 after; z = −4.34, p < 0.001, r = 0.52), and SDS scores increased (mean: 27.91 vs. 29.06 respectively; z = 2.91, p = 0.004, r = 0.35). Satisfaction with counseling was high (mean (SD) = 26.91 (2.68), on a scale where 6 = low and 30 = high satisfaction). HealthSeq participants felt that their decision regarding receiving personal results from WGS was more informed after genomic counseling. Further research comparing the impact of different genomic counseling models is needed.
Introduction
Whole exome sequencing (WES) and whole genome sequencing (WGS) are increasingly applied in clinical, research and even commercial settings. Multiple research studies have been designed to return personal results from WES/WGS to participants without an immediate clinical need, termed Bostensibly healthy^, in a predispositional individualized screening context (Biesecker et al. 2009; Church 2005; Gonzalez-Garay et al. 2013; Vassy et al. 2014, www.understandyourgenome.com) . At least one commercial laboratory is offering WES for screening for genetic disease risk in healthy adults (www. bmgl.com) . WGS/WES can concurrently provide individuals a broad range of insights including but not limited to their risk of developing rare monogenic and common polygenic diseases, medication safety and efficacy, and carrier status, along with non-health-related information such as ancestry. This increased scope creates corresponding challenges for informed decisionmaking; patients and research participants must simultaneously consider the risks and benefits of a wide range of potential health and non-health-related genetic findings.
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One major goal of genetic counseling is to help patients make informed decisions (www.nsgc.org) about obtaining genetic testing. An informed decision about genetic testing is based on adequate knowledge of the risks, benefits, limitations, and uncertainties associated with the testing, and is consistent with the individual's values (Marteau et al. 2001; Rimer et al. 2004) . For example, studies performed in the prenatal genetic counseling setting suggest that efforts to promote informed decision-making prior to genetic testing can reduce the probability of negative psychological outcomes occurring after testing (Ahman et al. 2010; Bernhardt et al. 2013; Kleinveld et al. 2009 ).
Efforts focused on ensuring informed decision-making in the context of personal genome sequencing for ostensibly healthy individuals are similarly likely to have benefits after the personal results have been returned. However, genome sequencing differs from single-or multiple-gene genetic testing in the purpose, scope, quantity, and type of information generated. The term 'genomic counseling' has been introduced in the literature, and we have adopted it for the purposes of this paper, to distinguish genetic counseling for genomebased testing from more traditional types of genetic counseling (Mills and Haga 2014; Ormond 2013 ). The differences between genetic and genomic counseling and how, if in any ways, genetic counseling will need to change to adapt to these differences is still under debate. Many authors have argued that the onset of widespread genomic testing will require a shift in the delivery model (Hooker et al. 2014; Mills and Haga 2014; Ormond 2013; Wicklund and Trepanier 2014) . One group has suggested that a client-centered counseling approach may be the most effective model for this type of test, while another has proposed that an education-based model may be a more appropriate approach given the volume of information that is generated (Hooker et al. 2014; Wicklund and Trepanier 2014) .
The necessary components of informed decision-making for personal WES/WGS and the optimal pre-test genomic counseling model for this kind of testing are still to be determined (Wicklund and Trepanier 2014) . To help inform the definition and development of genomic counseling, we analyzed data from before and after genomic counseling in the HealthSeq project, a pilot longitudinal cohort study designed to assess psychosocial and health-related outcomes in an unselected population of ostensibly healthy individuals offered health-and non-health-related WGS results. Participants' motivations, concerns and intentions to receive WGS results prior to genomic counseling, but after informed consent, were reported in detail in Sanderson et al. 2015a . We observed that prior to genomic counseling almost all participants (94.3 %) wanted all available findings and two-thirds (65.7 %) reported at least one concern about undergoing personal WGS. Here we: compare measures of participants' informed decisionmaking about what, if any, types of results to receive from WGS before and after the genomic counseling session; assess participants' genome sequencing knowledge, self-rated understanding, and concerns before and after counseling; and describe their satisfaction with the counseling experience and information provided. Our overarching goal is to contribute to the debate on how best to help individuals make informed decisions about personal WGS moving forwards.
Methods

Study Design
This was a mixed-method longitudinal cohort study in which in-depth interviews and questionnaires were administered to participants in the HealthSeq project before and after genomic counseling (see Online Resource 1 for flowchart describing the entire HealthSeq project). HealthSeq participants met with a certified genetic counselor prior to deciding whether to undergo WGS and deciding what types of personal information they would like to receive. This pre-test genomic counseling session was modeled on a traditional genetic counseling appointment with a client-centered approach and incorporated an educational video.
Participants and Procedures
Healthy individuals were recruited via flyers posted within the Mount Sinai Medical Center and word-of-mouth. Participants attended two in-person appointments held in the Mount Sinai Genetics Clinic. At the first in-person appointment (the T1 Bbaseline session^), potential participants were first required to consent to participating in the study and were taken through the informed consent document by the study coordinator who is a certified genetic counselor. The study coordinator then administered the first research interview, which comprised both closed-ended quantitative and open-ended qualitative components (the BT1-pre^interview and questionnaire). After this, participants attended the genomic counseling session with a different genetic counselor who was designated to provide the pre-test and post-test genomic counseling for all subjects in the study. This was followed by the administration of another questionnaire (the BT1-post^questionnaire) and then the blood draw. At the second in-person appointment (the Bresults session^), participants met with the dedicated genetic counselor and the study's dedicated medical geneticist for results disclosure. Participants were subsequently interviewed and completed questionnaires immediately following results disclosure (T2) and 1-week, 6-months, and 12-months post-results (T3-T5) (see Online Resource 1 for the study flowchart). The results from those interviews will be reported in future publications. Additional details regarding the study procedures are provided in a related publication (Sanderson et al. 2015a) . Financial compensation was not provided. The Institutional Review Board approved this study and informed consent was obtained from all individual participants included in the study. This report will focus on the results from the T1-pre and T1-post questionnaires that were administered immediately before and immediately after the pre-test genomic counseling session.
Informed Consent and Genomic Counseling
Informed Consent
Interested participants were emailed the informed consent document to read prior to their first appointment. Approximately 30 minutes at the start of the initial appointment were dedicated to the consent process, which included a description of the study, the study aims, what participating involved, and a general description of possible benefits and risks. During the description of the study, participants were informed that they could choose the types of genetic information they wanted returned and general categories of potential genetic information were outlined (e.g., BWe might find changes in genes that might increase or decrease your risk to develop conditions like heart disease and type 2 diabetes.^). Their preferences were documented during the genomic counseling session. Lastly, the consent process included procedures for ending participation, disclosure of financial interests, a description of how confidentiality is maintained, and documentation of participants' preferences for data and sample sharing.
Genomic Counseling
The pre-test genomic counseling session began with a discussion of the participant's motivations for participating in the HealthSeq project and expectations for their WGS results. Next, family and medical histories were obtained that were later incorporated into the variant analysis process. During this component of the counseling session, the counselor explained that the WGS testing might identify familial risks but that the research study was not designed to target one specific disease based on family history. If a strong family history suggesting a particular genetic risk factor (e.g., hereditary breast and ovarian cancer) was identified, then the appropriate genetics referral was provided, regardless of participation in the study or the participant's WGS results. After the family and medical history was reviewed, the counselor showed participants a 10-minute animated video about WGS that was designed by investigators at the Icahn School of Medicine at Mount Sinai (ISMMS) to help people make informed decisions about personal genome sequencing (see https://goo.gl/HV8ezJ) (Sanderson et al. 2015b ). The video covers basic genetic topics and describes WGS including the procedure and the types of information it might produce. It also describes some of the possible risks, benefits, and limitations of WGS. A discussion of the specific types of personal findings that might be returned, including ancestry, physical traits, pharmacogenomic variants, common polygenic disease risk and monogenic disease variants, followed the education component. To aid participants' decisionmaking about receiving their WGS results, the counselor provided anticipatory guidance through discussion of the potential implications of those results. The counselor also reiterated the risk, benefits and limitations of WGS in the context of the HealthSeq project. When appropriate, psychosocial concerns were then addressed. Lastly, the counselor documented the participant's choice of information they'd like to receive from the WGS and provided an explanation of how results would be returned.
Although the genomic counseling session naturally differed between participants, for consistency all the genomic counseling was performed by one genetic counselor, included the same components, and utilized the educational video to help ensure that all participants heard the same information about WGS. The counseling session lasted approximately one hour.
Measures
Questionnaire measures assessed informed decision-making before (T1-pre) and after (T1-post) pre-test genomic counseling including decisional conflict and decision satisfaction. Concerns and genome sequencing knowledge were also measured before and after genomic counseling. Sociodemographic characteristics were collected before genomic counseling. Satisfaction with genomic counseling, the information provided during the counseling session, and the WGS animation was assessed after counseling.
Informed Decision-Making
To assess desire for results from personal WGS, participants were asked whether they wanted to receive all, some or not any of their personal results (O'Connor 1995). They were then asked more specifically about their interest in receiving 9 types of genomic information (e.g., carrier for a rare genetic disorder, pharmacogenetics), but this was separate from the preferences they communicated to the genomic counselor (Sanderson et al. 2013) .
The Decisional Conflict Scale (DCS) was used to measure decisional conflict about choosing to receive results from WGS (O'Connor 1995). The DCS is reported as one overall score and five subscales: the informed subscale, the effective decision-making subscale, the support subscale, the values clarity subscale, and the uncertainty subscale (available from http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_ Decisional_Conflict.pdf, accessed June 17, 2015). DCS scores range from 0 (no decisional conflict) to 100 (high decisional conflict) where scores lower than 25 are associated with implementing decisions and scores exceeding 37.5 are associated with decision delay or feeling unsure about implementation.
To measure participants' satisfaction with their decision to receive personal information from WGS, the Satisfaction with Decision Scale (SDS) was administered (Holmes-Rovner et al. 1996) . The SDS score is a sum score with a range of 6 (low satisfaction) to 30 (high satisfaction).
Knowledge and Concerns
Participants' knowledge of genome sequencing was assessed with a measure developed for the ClinSeq study (Kaphingst et al. 2012) . Kaphingst et al. (2012) identified two factors that were subsequently labeled the BSequencing benefits knowledge^scale and the BSequencing limitations knowledge^scale. One item (A person's health habits, such as diet and exercise, can affect whether or not their genes cause diseases) did not load onto either scale in their factor analysis and is reported separately. The possible range of scale scores is 0 (indicating low knowledge) to 10 (indicating high knowledge). Scores for the knowledge about lifestyle item range from 1 (low knowledge) to 5 (high knowledge).
Participants self-rated their current understanding of genetics and WGS, and their knowledge of genetics and WGS compared to others. Participants were further asked to rate their knowledge of seven terms (Genome, Gene, DNA, Chromosome, Whole genome sequencing, Pharmacogenetics, and DNA variant of unknown significance) (Ishiyama et al. 2008) .
To ascertain concerns about participating in the HealthSeq study, participants were presented with 6 items that included, BConcerns related to not knowing how I will feel about my results^, and BConcerns related to potential privacy issues about my data^ (Bloss et al. 2010) .
Satisfaction with Genomic Counseling
Satisfaction with genomic counseling was measured with the Genetic Counseling Satisfaction Scale (GCSS) (DeMarco et al. 2004; Tercyak et al. 2001) . A total score was calculated by summing the scale items with a possible range of 6 to 30 with high scores correlating to high satisfaction.
Participants' satisfaction with the genomic counseling content was measured with 5 items adapted from previous research (Andermann et al. 2002) . These items were (1) How easy was it to understand; (2) The information was presented in a way that I could understand; (3) The information was easy to understand; (4) The information covered things I wanted to know; (5) The information provided me with new information. We explored whether items should be combined into a single satisfaction score, but the items did not load onto a single factor and are therefore reported separately. Participants were also asked to rate the amount of information they received about WGS as too much, too little, or the right amount (O'Connor and Cranney 1996) . Items 2-5 listed above were adapted to also measure satisfaction with the educational video on WGS.
Perceived utility of the genomic counseling content for decision-making about receiving results was assessed with one question adapted from previous research (Did the information you received help you decide whether to receive your personal results from whole genome sequencing?) (O'Connor and Cranney 1996). The same item was adapted to also ask about the perceived utility of the educational video.
Data Analysis
Socio-demographic characteristics, self-rated understanding of genetics and WGS, awareness of genetic terms, satisfaction with information, and perceived utility were described using frequencies, means, and standard deviations (SDs). The Kolmogorov-Smirnov test was used to examine whether continuous data variables were normally distributed. Because the data were skewed, the non-parametric Wilcoxon signed-rank test (for ordinal data) and McNemar's test (for categorical data) were used to compare differences between the two timepoints for each of the outcomes. To account for multiple hypothesis testing and in accordance with (Colquhoun 2014) , effect sizes were reported in addition to p-values for each significance test and p-values of ≤0.001 were considered significant. Effect sizes were calculated using r for ordinal data (Field 2013, p. 248) and Phi for categorical data (Field 2013, p. 740, 881) , and were described using Cohen's criteria of 0.1 for small effect, 0.3 for medium effect, and 0.5 for large effect (Cohen 1988) . Data was analyzed with IBM SPSS Statistics v22 (Chicago, IL).
Results
Participant Characteristics
Thirty-five participants were enrolled in the HealthSeq project. Forty-six percent of participants were female; the mean age was 47.5 years, 71 % were non-Hispanic White; all had a Bachelor's degree or higher; 83 % were employed full-time, and 49 % had an annual household income over $150,000 (Online Resource 2) (Sanderson et al. 2015a ).
Informed Decision-Making
After the genomic counseling session (T1-post), desire for personal WGS results did not change, all participants still wanted to receive personal WGS results, and almost all participants wanted to receive all personal results available (97.1 % after versus 94.3 % before genomic counseling; p = 0.99, ϕ = 0.00). Online Resource 6 lists participants' desire for results from 9 categories of genomic information albeit in a more hypothetical context; no significant change after genomic counseling was observed.
As Table 1 shows, DCS overall score and the subscale scores decreased after participants had genomic counseling. After counseling, the mean (SD) DCS overall score decreased to 5.94 (8.37) from 11.34 (10.80) (p < 0.001, r = 0.52). Mean scores on the five decisional conflict subscales (informed, effective decision-making, support, values clarity, uncertainty) were also generally lower after, as compared to before, genomic counseling (p = 0.024, r = 0.27; p = 0.001, r = 0.39; p = 0.002, r = 0.38; p = 0.002, r = 0.37; p = 0.001, r = 0.38; respectively: Table 1 ). These findings suggest that participants felt more informed about their decision, more supported in their decision-making, had greater clarity regarding their values, felt less uncertain, and were generally more satisfied with their decision after having genomic counseling.
The mean (SD) SDS score after genomic counseling increased to 29.06 (2.04) from 27.91 (2.69) prior to genomic counseling, suggesting that participants were more satisfied with their decision to receive WGS results after counseling (p = 0.004, r = 0.35: Table 1 ).
Knowledge and Concerns
Knowledge about the benefits and limitations of WGS did not increase after the genomic counseling session. As Table 2 shows, the mean (SD) score for the knowledge about benefits scale was 8.46 (1.95) before vs. 8.74 (1.88) after genomic counseling (p = 0.22, r = 0.15); for the knowledge about limitations scale was 8.54 (2.03) before vs. 8.80 (2.11) after genomic counseling (p = 0.31, r = 0.12); and for the knowledge about lifestyle-genomics item was 4.37 (1.19) before vs. 4.66 (0.77) after genomic counseling (p = 0.084, r = 0.21) (Online Resource 4).
Self-rated knowledge of WGS-related terms did increase after genomic counseling. The mean (SD) number of WGS-related terms that participants stated that they knew the meaning of rose from 4.43 (2.48) before genomic counseling to 6.37 (1.99) after genomic counseling (p < 0.001, r = 0.46: Table 2 ). Specifically, 51.4 % of participants reported that they knew the meaning of the term whole genome sequencing before versus 91.4 % after genomic counseling (p < 0.001, ϕ = 0.42: Table 2 ). Self-rated knowledge of the terms genome, pharmacogenetics, and DNA variant of unknown significance also increased from before to Table 2 ). However, the proportion of individuals reporting that they knew the meaning of the terms DNA and chromosome did not change after genomic counseling (both, 77.1 %, p = 0.13, = 0.18: Table 2 ). Participants' self-rated understanding of WGS both generally and compared to others also increased after genomic counseling (p < 0.001, r = 0.49; p = 0.005, r = 0.34; respectively; Online Resource 4).
Genomic counseling had little impact on participants' concerns related to receiving personal WGS results: as Table 2 shows, 65.7 % of participants reported at least one concern after genomic counseling, the same as before (p = 0.99, = 0.00). Additional details about participants' concerns can be found in Online Resource 5.
Satisfaction with Genomic Counseling
Participants reported being satisfied with the genomic counseling session with a mean (SD) GCSS score of 26.91 (2.68) out of 30 (Table 3 ). For 5 of the 6 individual GCSS items mean scores ranged from 4.46 to 4.83 out of 5, while the mean score for the item BI felt better about my health after meeting with my genetic counselor^was lower at 3.66 (Online Resource 3). Over 94 % of participants stated that the genomic counseling content was presented in a way that they could understand and that it covered things they wanted to know while 80 % of participants felt they received new information (Table 3 ). The majority (88.6 %) stated that the information they received about WGS was the Bright amount^ (Table 3) . Participants also reported being very satisfied with the animation with over 80 % stating that the animation: presented information in a way they could understand; was easy to understand; and covered things they wanted to know (Online Resource 3).
After the genomic counseling session, 57.1 % stated that the information they received overall, and 31.4 % stated that the animated video specifically, had helped them decide whether to receive personal results from WGS (Table 3 and Online Resource 3).
Discussion
This study examined the impact of pre-test genomic counseling on informed decision-making among participants who were deciding to undergo personal WGS in the HealthSeq project. Although desire to receive personal results from WGS did not change after in-person genomic counseling, participants reported making a more informed decision about having their genomes sequenced and receiving personal genomic information after counseling. Data showed that participants had lower decisional conflict and increased satisfaction with their decision to obtain personal genomic information from WGS after compared to before genomic counseling. Specifically, participants felt less uncertain, had greater values clarity, and felt more supported and informed in their decision-making. Participants also self-reported an increase in understanding of genetics and WGS, and an increase in knowledge of WGSrelated terms including whole genome sequencing, pharmacogenomics, and DNA variant of unknown significance. These findings suggest that pre-test genomic counseling and education may have positive effects on WGS knowledge and that participants feel more informed about WGS after the genomic counseling. In addition, over half of the participants reported that the experience helped them make their decision, further suggesting that participants were more confident in their decision after counseling. Participants were also highly satisfied with the genomic counseling.
We expected, but did not observe, the genomic counseling experience to increase knowledge about the limitations and benefits of genome sequencing as measured with the Kaphingst et al. 2012 scale. While the lack of increased genome sequencing knowledge here may reflect the genomic counseling content, the lack of differences may also be due to the fact that the majority of participants' baseline scores were at the upper end of the testing range, which limited our ability to measure any significant variation in scores. HealthSeq participants are predominantly of higher education level, many with previous exposure to genetics and genomics, and mean baseline scores for both genome sequencing knowledge subscales were approximately 8.5 out of 10. The ClinSeq study used the same measure to assess increases in genome sequencing knowledge after informed consent and reported baseline subscale scores of approximately 7.0, and increases for both genome sequencing knowledge subscales (Kaphingst et al. 2012) . This is the only published measure available to objectively assess genomic knowledge. Our findings highlight the need for a genomic knowledge measure that is sufficiently sensitive for use with cohorts of higher educational attainment and individuals with a background in genetics, healthcare, and/or the sciences.
This study explored participants' concerns regarding personal WGS testing. Prior to genomic counseling, some participants expressed concerns about learning disease risk, and many were concerned about the psychological impact of the results, and the privacy of their data (Sanderson et al. 2015a ). Genomic counseling did not impact these concerns; in the present analyses, we found that the majority of participants expressed the same number of concerns before and after counseling. A thorough discussion of privacy issues and the risk of discrimination for medical insurance as well as life, disability, and long-term care insurance during the informed consent process, which took place prior to the baseline questionnaire, may have reduced the impact of the genomic counseling on these concerns. Also, WGS differs from other types of genetic testing (e.g. targeted BRCA1/2 testing) because the test does not target one specific disease or set of diseases (e.g. breast and ovarian cancer), but rather produces a range of unpredictable personal results. Therefore, participants in the HealthSeq project and other WGS contexts understandably may find it difficult to prepare themselves psychologically for the results they may receive via WGS, even with genomic counseling. Addressing individuals' concerns regarding the future psychological impact of personal results from WGS, before it is known what or if any disease risks or diagnoses are going to be identified, is a particular challenge of genomic counseling.
We anticipate that there will be some additional challenges to genomic counseling for WGS with healthy individuals. In addition to managing the expectations of participants by helping them understand the limitations of the technology, genetic counselors will need to address the broad scope of WGS results. The term Bwhole^genome sequencing might promote misconceptions such as believing that the genome is sequenced in its entirety, that all genetic aberrations are identifiable, or that a negative test result equals a Bclean bill of health^. Genetic counselors may need to focus more on the implications of negative results rather than the consequences of positive results.
The genomic counseling for this study modeled a clinical, client-centered approach and included two in-person counseling sessions, the first during decision-making about whether to pursue genome sequencing, and the second when results were returned. Our study provides evidence that this approach can reduce decisional conflict and increase satisfaction with decisions made. We recognize, however, that this model is time-intensive for all parties involved (HealthSeq participants spent a minimum of two hours with a genetic counselor and one hour with a medical geneticist) and that access to genetic counselors may be limited. The approach used in the HealthSeq project is one point on a spectrum that may include other modalities such as telephone counseling, telegenetics (web-based counseling), and return of results by primary care physicians. Comparing HealthSeq to other personal genome sequencing studies with different counseling approaches (Church 2005; Gonzalez-Garay et al. 2013; Vassy et al. 2014, www.understandyourgenome.com) may help improve our understanding of how best to enable informed decisionmaking and return genomic results from WES/WGS. For example, participants in the MedSeq Project at Harvard are recruited from primary care and cardiology clinics and results are returned through the physicians (Vassy et al. 2014) . The physicians participating in the MedSeq Project are able to consult with genetic counselors and medical geneticists, but the participating patients do not have direct contact with these specialists themselves. In a WES study by investigators at the University of Texas Health Science Center (Gonzalez-Garay et al. 2013) , healthy participants attended an 8-hour education program prior to enrolling, and then the WES results were returned to them by an internist and a medical geneticist; these patients also did not interact directly with a genetic counselor.
Study Limitations and Research Recommendations
The HealthSeq project has a small sample size and the cohort was made up of highly motivated, earlier adopters of this technology who were not representative of the general population (participants were predominantly White non-Hispanic, educated, and of high socio-economic status, although there were roughly equal proportions of men and women), and therefore the results may not be generalizable. Another limitation is that the HealthSeq protocol required participants to undergo informed consent prior to administration of the T1 pre-counseling questionnaire, which could have influenced participants' responses at baseline and should be a consideration when interpreting these results. It would be valuable for future research to incorporate a two-phase consent process that would minimize education/counseling prior to the baseline timepoint. This paper focused on the impact of pre-test genomic counseling at the time of initial decision-making in the HealthSeq project, but it will also be important to understand how participants felt about their pre-test genomic counseling experiences after they received their personal genomic results. This will further improve understanding of how best to help individuals make informed decisions as well as the best methods for returning genomic information and for helping participants interpret and cope with their results. We will be able to shed some light on these questions upon completion of the follow-up interviews currently being conducted in the HealthSeq project.
Another consideration is whether and how existing validated reliable measures such as the Genetic Counseling Satisfaction Scale (GCSS) should be adapted for the genomic counseling context. For example, on the GCSS, participants were less likely to agree with one of the items (BI feel better about my health after meeting with my genetic counselor^) than the other five items. This may reflect the fact that ostensibly healthy individuals do not have the same health-related concerns to address during counseling as patients in other genetic counseling contexts, such as patients at high risk of breast cancer who are considering BRCA1/2 genetic testing. Developing a valid and reliable alternative version of this scale that can be used with healthy individuals considering WGS would be valuable.
Conclusions
In the HealthSeq project, participants who were considering personal WGS testing valued the in-person genomic counseling they received at baseline. After counseling, participants reported significant decreases in decisional conflict and increases in decision satisfaction. They also reported being highly satisfied with the genomic counseling model used in this study. Additional research is needed to fully elucidate the most effective approach for preparing patients and research participants to undergo personal genome sequencing.
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